Related Experiment Video

Updated: Aug 16, 2026

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells

Sabrina Ottaviani1, Didier Colau, Pierre van der Bruggen

  • 1Ludwig Institute for Cancer Research and Institute of Cellular Pathology, Cellular Genetics Unit, Université de Louvain, 74 avenue Hippocrate, UCL 7459, B-1200 Brussels, Belgium.

Cancer Immunology, Immunotherapy : CII
|September 10, 2005
PubMed

Insights

Researchers identified a novel MAGE-4 peptide (NYKRCFPVI) presented by HLA-A24 molecules for cancer immunotherapy. This peptide shows promise in targeting various carcinomas, especially when tumor cells are treated with IFN-gamma.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Cancer-germline genes, like the MAGE family, are expressed in tumors and male germ cells but not other normal tissues.
  • These genes encode tumor-specific antigens crucial for cancer immunotherapy development.
  • MAGE-4 is frequently expressed in various carcinomas, making it a promising target for immunotherapy.

Purpose of the Study:

  • To identify novel MAGE-4 antigenic peptides for cancer immunotherapy.
  • To investigate the potential of the MAGE-4 peptide NYKRCFPVI presented by HLA-A*2402.

Main Methods:

  • Folding of HLA-A*2402 soluble molecules with the candidate peptide NYKRCFPVI (amino acids 143-151 of MAGE-4).
  • Utilizing A24/MAGE-4 multimers to isolate cytolytic T cell clones.
  • Assessing the lysis of A24 carcinoma cells expressing MAGE-4 by isolated T cell clones.
  • Evaluating the effect of IFN-gamma pre-treatment on antigenic peptide processing in tumor cells.

Main Results:

  • A cytolytic T cell clone recognizing the MAGE-4 peptide NYKRCFPVI was isolated from a healthy donor.
  • This T cell clone specifically lysed MAGE-4-expressing A24 carcinoma cells.
  • Peptide processing was enhanced in tumor cells treated with IFN-gamma.
  • The MAGE-4 peptide is presented by the widely expressed HLA-A24 molecule.

Conclusions:

  • The MAGE-4 peptide NYKRCFPVI is a potential target for HLA-A24-restricted cancer immunotherapy.
  • Its efficacy may be enhanced by IFN-gamma pre-treatment of tumor cells.
  • The broad expression of HLA-A24 across ethnic groups supports its potential for widespread application.

More Related Videos

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Related Concept Videos

Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Antigen Presenting Cells01:22

Antigen Presenting Cells

The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...